A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Clinical trial NCT06048315 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06048315
Sponsor: Degan Lu
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Lung Cancer TKI Resistance EGFR Sensitive Mutation Anlotinib Pianzumab

Start date: 2023-09-01
Primary completion: 2026-06-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.